Quzyttir®
Cetirizine HCl Injection 10 mg/mL

INDICATIONS AND USAGE[1]
Quzyttir® is a histamine-1 (H_1) receptor antagonist indicated for the treatment of acute urticaria in adults and children 6 months of age and older

Limitations of Use:
Not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function

DOSAGE AND ADMINISTRATION[1]
For intravenous administration only

Recommended dosages:
- Adults and adolescents ≥ 12 years: 10 mg
- Children 6 to 11 years: 5 mg or 10 mg
- Children 6 months to 5 years: 2.5 mg

Recommended dosage regimen is once every 24 hours as needed for acute urticaria

Please see Important Safety Information on reverse side.

NDC 70720-100-25[1]:
Carton containing 25 single-use vials (10 mg/mL cetirizine hydrochloride)

NDC 70720-100-10[1]:
Carton containing 1 single-use vial (10 mg/mL cetirizine hydrochloride)

Authorized Specialty Distributors

Name	Customer Service	Order Times
Besse Medical	800-543-2111	Monday-Thursday 8:30 AM-7 PM ET, Friday 8:30 AM-5 PM ET
Cardinal Specialty	Oncology: 877-453-3972 Other Specialties: 866-300-3838	Monday-Friday 8 AM-7 PM ET
CuraScript SD Specialty Distribution	877-599-7748	Monday-Friday 8:30 AM-7 PM ET
McKesson Plasma and Biologics	877-625-2566	Monday-Friday 9 AM-7:30 PM ET
McKesson Specialty	Oncology: 800-482-6700 Other Specialties: 855-477-9800	Monday-Friday 8 AM-8 PM ET
Metro Medical	800-768-2002	Monday-Friday 8 AM-8 PM ET
Oncology Supply	800-633-7555	Monday-Friday 9 AM-8 PM ET

1. QUZYTTIR (cetirizine hydrochloride injection) [package insert]. Deerfield, IL: TerSera Therapeutics LLC; 2020.

TerSera SupportSource

Additional Questions?
Please contact TerSera SupportSource at 1-855-686-8725, Monday-Friday, 9 AM-6 PM ET.

Indication and Important Safety Information
QUZYTTIR® (cetirizine hydrochloride injection), for intravenous use

INDICATIONS AND USAGE
QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

Limitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

IMPORTANT SAFETY INFORMATION
Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving, or when operating potentially dangerous machinery. Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

The most common adverse reactions (incidence ≥2%) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

For more information, please see the accompanying full Prescribing Information for QUZYTTIR.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

TerSera® therapeutics

Quzyttir®
Cetirizine HCl Injection
10 mg/mL